Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Apostolopoulos

Showing results (1-10 of 89) with videos related to

Pageof 9
Sort By:
Current Opinion in Molecular Therapeutics|March 16, 2001
The evolution of DNA vaccinesV Apostolopoulos, M Plebanski
Current Medicinal Chemistry|March 26, 2005
Rational Peptide-based vaccine design for cancer immunotherapeutic applicationsE Lazoura, V Apostolopoulos
Current Molecular Medicine|March 20, 2002
Role of the mannose receptor in the immune responseV Apostolopoulos, I F McKenzie
Gut|May 14, 1999
Towards immunotherapy of pancreatic cancerI F McKenzie, V Apostolopoulos
Critical Reviews in Immunology|January 1, 1994
Cellular mucins: targets for immunotherapyV Apostolopoulos, I F McKenzie
Mini Reviews in Medicinal Chemistry|October 9, 2002
Antihypertensive drugs that act on Renin-Angiotensin System with emphasis in AT(1) antagonistsT Mavromoustakos, V Apostolopoulos, J Matsoukas
Mini Reviews in Medicinal Chemistry|October 9, 2002
Designing peptide mimetics for the treatment of multiple sclerosisJ Matsoukas, V Apostolopoulos, T Mavromoustakos
Nature Medicine|March 21, 1998
MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoralV Apostolopoulos, C Osinski, I F McKenzie
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 29, 1998
Cyclophosphamide enhances the CTL precursor frequency in mice immunized with MUC1-mannan fusion protein (M-FP)V Apostolopoulos, V Popovski, I F McKenzie
Vaccine|February 13, 2001
A 16-mer peptide (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the Class I pathwayG A Pietersz, W Li, V Apostolopoulos
Pageof 9

Showing results (1-10 of 89) with videos related to

Sort By:
Pageof 9
Current Opinion in Molecular Therapeutics|March 16, 2001
The evolution of DNA vaccinesV Apostolopoulos, M Plebanski
Current Medicinal Chemistry|March 26, 2005
Rational Peptide-based vaccine design for cancer immunotherapeutic applicationsE Lazoura, V Apostolopoulos
Current Molecular Medicine|March 20, 2002
Role of the mannose receptor in the immune responseV Apostolopoulos, I F McKenzie
Gut|May 14, 1999
Towards immunotherapy of pancreatic cancerI F McKenzie, V Apostolopoulos
Critical Reviews in Immunology|January 1, 1994
Cellular mucins: targets for immunotherapyV Apostolopoulos, I F McKenzie
Mini Reviews in Medicinal Chemistry|October 9, 2002
Antihypertensive drugs that act on Renin-Angiotensin System with emphasis in AT(1) antagonistsT Mavromoustakos, V Apostolopoulos, J Matsoukas
Mini Reviews in Medicinal Chemistry|October 9, 2002
Designing peptide mimetics for the treatment of multiple sclerosisJ Matsoukas, V Apostolopoulos, T Mavromoustakos
Nature Medicine|March 21, 1998
MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoralV Apostolopoulos, C Osinski, I F McKenzie
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 29, 1998
Cyclophosphamide enhances the CTL precursor frequency in mice immunized with MUC1-mannan fusion protein (M-FP)V Apostolopoulos, V Popovski, I F McKenzie
Vaccine|February 13, 2001
A 16-mer peptide (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the Class I pathwayG A Pietersz, W Li, V Apostolopoulos
Pageof 9